Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Steve Grasso, CEO of Grasso Global, joins CNBC's 'The Exchange' to discuss outlooks on three stocks: Supermicro, Novo Nordisk ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Novo Nordisk stock faces bearish technicals, but analysts forecast nearly 46% upside. Novo inks $285 million Ascendis deal, ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, ...

Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...